RADL3.SA
Raia Drogasil S.A.
São PauloBRLEQUITY
Healthcare
DELAYED
Last price
18.43
▲ 0.86 (4.89%)
MARKET · —
Price
Open
17.65
Prev close
17.57
Day high
18.62
Day low
17.62
Volume
10.71M
Market cap
$32.23B
P/E (TTM)
21.68
52W range
16.21 – 27.42
Trailing performance
Returnvs SPY
1W
-3.99%
-2.6%
1M
-3.94%
-7.7%
3M
-3.41%
-6.5%
6M
-33.47%
-44.5%
YTD
-25.07%
-37.4%
1Y
+2.70%
-17.3%
3Y
-34.71%
-108.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$32.23B
Enterprise value$40.17B
Revenue (TTM)$46.53B
Gross profit$14.10B
EBITDA$3.86B
Net income$1.40B
EPS (TTM)$0.85
Free cash flow$2.18B
Total cash$652.95M
Total debt$8.59B
Book value / share$4.17
Shares outstanding1.75B
Float1.31B
Short % of float—
Dividend yield2.39%
Beta (5Y)0.01
Valuation & profitability ratios
Trailing P/E21.68
Forward P/E15.79
PEG ratio0.27
Price / sales—
Price / book4.42
EV / revenue0.86
EV / EBITDA10.41
Gross margin30.30%
Operating margin7.58%
Profit margin2.89%
Return on equity19.99%
Return on assets7.80%
Debt / equity117.86
Current ratio1.41
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $44.25B | $38.87B | $33.97B | $29.07B |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $1.34B | $1.28B | $1.15B | $996.11M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | $1.34B | $1.28B | $1.15B | $996.11M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.24 | 0.21 | -12.4% |
| Mar 2026 | 0.17 | 0.18 | +1.3% |
| Dec 2025 | 0.21 | 0.18 | -12.1% |
| Sep 2025 | 0.21 | 0.24 | +15.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.25 | 1 | $12.05B | +6.9% |
| Next quarter | 0.25 | 1 | $12.57B | +3.8% |
| Current year | 0.89 | 5 | $45.55B | +2.9% |
| Next year | 1.17 | 7 | $52.04B | +14.2% |
Analyst targets & ownership
Mean target$25.25
High target$31.00
Low target$18.00
Implied upside37.02%
Analyst count15
ConsensusBUY
Strong buy / Buy3 / 8
Hold3
Sell / Strong sell1 / 0
Held by insiders25.07%
Held by institutions58.06%
Institutions holding344
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
438.34M
Total on file
Moving averages & technicals
SMA 10
18.14
+1.61% from price
SMA 20
18.46
-4.81% from price
SMA 50
17.94
-2.06% from price
SMA 100
19.36
-4.80% from price
SMA 200
21.58
-18.57% from price
EMA 12
18.05
+2.13% from price
EMA 26
18.24
+1.06% from price
EMA 50
18.45
-0.09% from price
RSI (14)
43.6
Neutral
MACD (12,26,9)
-0.19
Hist -0.21
ATR (14)
0.74
4.22% of price
Realised vol 30D
40.7%
Annualised
Bollinger upper
20.39
20, 2σ
Bollinger lower
16.52
20, 2σ
50 / 200 cross
Death
17.94 vs 21.58
Trend bias
Below 200
-18.57%
Risk profile
Beta vs SPY
-0.20
Less volatile than market
Correlation to SPY
-0.07
Largely independent
Realised vol 30D
40.7%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-39.8%
Peak to trough
Max drawdown 5Y
-55.6%
Peak to trough
ATR 14
0.74
4.22% of price
Beta (reported)
0.01
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Dozens of civilians killed, kidnapped as jihadists clash in Nigeria
AFP · 12m ago
EOG Resources (EOG) Stock Still Looks A Bargain On Earnings Yet Fully Priced On Returns
Simply Wall St. · 15m ago
Artemis Gold (TSXV:ARTG) Stock Still Looks Reasonable Despite Its 7x Run
Simply Wall St. · 15m ago
Why Ocular Therapeutix (OCUL) Is Up 10.4% After Q2 Beat And AXPAXLI Phase 3 Timeline Update
Simply Wall St. · 15m ago
Scholar Rock (SRRK) Stock Looks Stretched On Book Value But Strong On Returns
Simply Wall St. · 15m ago
Regions Financial (RF) Stock Could Trade At A 48% Discount On Earnings Power
Simply Wall St. · 15m ago
Tonies (DB:TNIE) On Half Year Results, Can The Bull Case Still Support Fair Value?
Simply Wall St. · 16m ago
Hut 8 (HUT) Gets Court Approved Notice For $2,350,000 Settlement
Simply Wall St. · 16m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.